Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (91-100 of 501) with videos related to

Pageof 51
Sort By:
Cancer|May 10, 2002
The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma RegistryClaus Garbe, Ulf Ellwanger, Michael Tronnier, et al.
British Journal of Cancer|June 29, 2018
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodiesNikolaus B Wagner, Andrea Forschner, Ulrike Leiter, et al.
The Oncologist|January 8, 2011
Systematic review of medical treatment in melanoma: current status and future prospectsClaus Garbe, Thomas K Eigentler, Ulrich Keilholz, et al.
Experimental Dermatology|November 9, 2010
Absence of merkel cell polyoma virus in cutaneous melanomaIvette Koburger, Diana Meckbach, Gisela Metzler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and ScotlandUlrike Keim, Alexander Katalinic, Bernd Holleczek, et al.
European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Cutaneous squamous cell carcinoma 1986-2019 in Germany: Incidence, anatomical site, staging, and histologic subtypesJulius Balkenhol, Thomas Dirschka, Conrad Falkenberg, et al.
Proteomics|March 19, 2016
High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' seraDanilo Ritz, Andreas Gloger, Benjamin Weide, et al.
International Journal of Molecular Sciences|October 16, 2025
Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant MelanomaCorinna Kosnopfel, Tobias Sinnberg, Shrunal Mane, et al.
Cancer Immunology, Immunotherapy : CII|September 16, 2018
Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapyHenning Zelba, Jonas Bochem, Graham Pawelec, et al.
The Lancet. Oncology|December 4, 2018
Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?Jean Jacques Grob, Claus Garbe, Paolo Ascierto, et al.
Pageof 51

Showing results (91-100 of 501) with videos related to

Sort By:
Pageof 51
Cancer|May 10, 2002
The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma RegistryClaus Garbe, Ulf Ellwanger, Michael Tronnier, et al.
British Journal of Cancer|June 29, 2018
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodiesNikolaus B Wagner, Andrea Forschner, Ulrike Leiter, et al.
The Oncologist|January 8, 2011
Systematic review of medical treatment in melanoma: current status and future prospectsClaus Garbe, Thomas K Eigentler, Ulrich Keilholz, et al.
Experimental Dermatology|November 9, 2010
Absence of merkel cell polyoma virus in cutaneous melanomaIvette Koburger, Diana Meckbach, Gisela Metzler, et al.
European Journal of Cancer (Oxford, England : 1990)|February 21, 2023
Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and ScotlandUlrike Keim, Alexander Katalinic, Bernd Holleczek, et al.
European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Cutaneous squamous cell carcinoma 1986-2019 in Germany: Incidence, anatomical site, staging, and histologic subtypesJulius Balkenhol, Thomas Dirschka, Conrad Falkenberg, et al.
Proteomics|March 19, 2016
High-sensitivity HLA class I peptidome analysis enables a precise definition of peptide motifs and the identification of peptides from cell lines and patients' seraDanilo Ritz, Andreas Gloger, Benjamin Weide, et al.
International Journal of Molecular Sciences|October 16, 2025
Combinatorial ERK Inhibition Enhances MAPK Pathway Suppression in BRAF-Mutant MelanomaCorinna Kosnopfel, Tobias Sinnberg, Shrunal Mane, et al.
Cancer Immunology, Immunotherapy : CII|September 16, 2018
Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapyHenning Zelba, Jonas Bochem, Graham Pawelec, et al.
The Lancet. Oncology|December 4, 2018
Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?Jean Jacques Grob, Claus Garbe, Paolo Ascierto, et al.
Pageof 51